Guru Analysis Of ZIOPHARM Oncology, Inc. (ZIOP)

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) enjoyed a -0.87% run-up in share price since hitting record low of $4.03. The stock managed -5.66% fall and now stands at $4 as of 12/06/2017. At recent session, the prices were hovering between $3.9 and $4.26. This company shares are 212.5% off its target price of $12.5 and the current market capitalization stands at $570.32M. The recent change has given its price a -21.58% deficit over SMA 50 and -49.24% deficit over its 52-week high. The stock witnessed -14.35% declines, -35.9% declines and -30.43% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ZIOP’s volatility during a week at 6.81% and during a month it has been found around 7.79%.

ZIOPHARM Oncology, Inc. (ZIOP) Top Holders

Institutional investors currently hold around $247 million or 49.6% in ZIOP stock. Look at its top three institutional owners. Third Security, Llc owns $41.17 million in ZIOPHARM Oncology, Inc., which represents roughly 7.22% of the company’s market cap and approximately 16.67% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 8,219,206 shares of the stock are valued at $34.85 million. The third largest holder is Vanguard Group Inc, which currently holds $34.71 million worth of this stock and that ownership represents nearly 6.09% of its market capitalization.

ZIOPHARM Oncology, Inc. 13F Filings

At the end of 09/30/2017 reporting period, 46 institutional holders increased their position in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) by some 1,872,010 shares, 48 decreased positions by 4,321,848 and 43 held positions by 52,017,959. That puts total institutional holdings at 58,211,817 shares, according to SEC filings. The stock grabbed 11 new institutional investments totaling 290,612 shares while 12 institutional investors sold out their entire positions totaling 414,069 shares.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Insider Trades

Multiple company employees have indulged in significant insider trading. ZIOPHARM Oncology, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that EVP and Chief Business Officer Mauney David M Md has acquired 4,270 shares of ZIOPHARM Oncology, Inc. (ZIOP) in trading session dated Nov. 08, 2017. These shares are worth $19,984 and were traded at $4.68 each. The SEC filing shows that Cooper Laurence James Neil performed a purchase of 6,440 shares. The CEO added these shares by way of transaction on Nov. 08, 2017. The company’s shares were assimilated at $4.68 per share worth to an investment of some $30,139 on account of Cooper Laurence James Neil.

COO, CLO, and Secretary, Belbel Caesar J, sold 153,333 common shares of ZIOPHARM Oncology, Inc. (ZIOP) in the open market. In a transaction dated Nov. 19, 2015, the shares were put up for sale at an average price of $12.84, raking in a sum of $1,968,796. After this sale, 59,201 common shares of ZIOP are directly owned by the insider, with total stake valued at $236,804.

In the transaction dated Jun. 09, 2015, the great number of shares disposed came courtesy the Executive Vice President R&D; Lebel Francois disposed a total of 50,000 shares at an average price of $10.12, amounting to approximately $506,000. The insider now directly owns shares worth $.

ZIOPHARM Oncology, Inc. (ZIOP) Analyst Guide

Several analysts have released their opinion on ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), with 2 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.2 average brokerage recommendation.

Previous articleThe Biggest 3 Holders Of Venator Materials PLC (VNTR)
Next articleSequans Communications S.A. (SQNS) loses confidence of 10 institutional holders